Is adenocarcinoma of the right lung a difficult disease to treat?

Adenocarcinoma of the lungs is not the most difficult** type of lung cancer. One of the most difficult types of lung cancer is small cell lung cancer, because its tumor cell multiplication time is short, the disease is severe, the degree of malignancy is high, and the course of the disease is short, although the tumor is sensitive to chemoradiotherapy, but after the lesion is stopped, it is very easy to have extensive external invasion and metastasis, so the patient's survival time is short, the prognosis is poor, and the clinical difficulty is greater.

The rate and survival rate of lung cancer involve too many factors, such as the patient's age, basic physical condition, organ function, specific pathological stage, tumor genotype, tumor differentiation, ** effect, patient's economic status, patient's psychological state, etc. Calmly faced, positive**, the future can be expected.

There is a chance. Lung adenocarcinoma is a common tumor in the lungs, its first lies in early detection, early diagnosis, early **, the earlier the treatment of the tumor, the lower the rate, the higher the survival rate, especially when the tumor has not metastasized, and even when the mucosal layer, deep muscle layer, and surrounding tissues are not too infiltrated, surgical resection can be said to directly block the development of the tumor. If you enter an advanced stage, it is difficult to completely**.

Surgery and chemoradiation therapy do not completely remove the tumor cells that have spread. The tumor has entered an advanced stage, distant metastasis has occurred, the common metastasis is lymph nodes, other lung lobes, liver, brain and bones, infiltration around the tumor, it is difficult to completely remove the primary lesion after a wide range of surgery, many metastases can not be completely removed by surgery, chemoradiotherapy, the tumor and the chance of progression is very large, the purpose of the tumor is more palliative, limiting, inhibiting the progress of the tumor, improving the quality of life, and increasing the survival time.

Analysis: Lung adenocarcinoma is a type of lung cancer, which is a non-small cell carcinoma, which is different from squamous cell lung cancer, lung adenocarcinoma is more likely to occur in women and smokers. Lung adenocarcinoma is a type of lung cancer, which is a non-small cell carcinoma, which is different from squamous cell lung cancer, which is more likely to occur in women and smokers.

It is accompanied by symptoms such as chest tightness, chest pain and dyspnea, among which the overall chance of early lung cancer is relatively high.

Adenocarcinoma of the lungs means that within 5 years, it will not. Therefore, in the early stage of lung adenocarcinoma, if it is detected in time, the patient will immediately enter the hospital for ** or there is a 70% chance **.

OK**. It's perfectly okay to detect it early and start it, but not at an advanced stage.

Lung adenocarcinoma, called cancer in Western medicine, is not as serious as cancer, to put it bluntly, it is a serious carbuncle, which can be controlled by simple Chinese medicine in 3 months, and can be cured in one year.

Lung adenocarcinoma accounts for about 25% of primary lung cancers. It is more likely to occur in women and non-smokers. Originates from the bronchial mucosal epithelium and, rarely, from the mucous glands of the large bronchi.

The incidence is lower than that of squamous cell carcinoma and undifferentiated carcinoma, and the age of onset is younger, and it is relatively more common in women. Mucous glands that grow mostly in the small bronchi at the edge of the lungs, and adenocarcinoma is the most common type of peripheral lung cancer.

Lung adenocarcinoma is a relatively benign lung cancer, as long as it is timely, the early prognosis is very good, and the current technology of traditional Chinese medicine diagnosis and treatment of tumors is very mature, and the possibility of cure is still relatively large.

It is possible to have lung adenocarcinoma in the early stage, and lung adenocarcinoma is generally benign.

In the early stage, it can be **timely**, and the current NK immunity** has a good effect.

Yes, you can use biological immunity**.

Hello! This friend can go to the hospital for surgery** immediately, please consult your local doctor for details.

The first method of lung cancer is divided into two parts, first obtain the pathology and then divide lung cancer into two categories: small cell lung cancer and non-small cell lung cancer. In the case of small cell lung cancer, chemotherapy combined with radiotherapy is the main combination**, and in the case of non-small cell lung cancer, it should be subdivided into adenocarcinoma or non-adenocarcinoma. In the case of adenocarcinoma, the decision to use targeted drugs depends on the gene mutation.

If it is non-adenocarcinoma, it is mainly comprehensive**. For all non-small cell lung cancers, its clinical stage is first assessed. Before stage A, it is necessary to strive for surgical resection, that is, **surgery, and then decide the follow-up ** according to the pathology after the operation.

If the patient cannot be operated, it is necessary to consider whether it is genetically mutated or genetically non-mutated, and according to these, the pathway of targeting ** or the path of chemoradiotherapy should be decided. There are still some advanced lung cancers in the clinic, there is no chance of surgery, radiotherapy, chemotherapy, these patients, to give the best support**, or through genetic testing, to apply some corresponding molecular targeted drugs**, and even the latest immunity**, to prolong the survival of patients.

Lung adenocarcinoma is the most common type of lung cancer (about 40%), with a very high degree of malignancy, no special symptoms in the early stage, and often has progressed to an advanced stage by the time it is diagnosed.

Lung adenocarcinoma is a non-small cell lung cancer, and advanced lung adenocarcinoma** can be very tricky. In recent years, the advent of targeted and immune** has provided a new choice for patients with lung adenocarcinoma.

So, how to choose chemotherapy, targeting**, and immunity**?

November is the Global Lung Cancer Awareness Month, and H&Q Good Doctor Platform invited Dr. Michael Castro, a well-known oncologist in the United States, to answer questions for patients with advanced lung adenocarcinoma.

Lung adenocarcinoma is not the most difficult type of lung cancer, whether the disease can be judged by the type of pathology, the most important thing is to determine the extent of dissemination and clinical stage. If it is a relatively early stage and isolated disease, especially carcinoma in situ, microinvasive lung adenocarcinoma, or invasive lung adenocarcinoma. However, smaller ground-glass nodules are easier to achieve by sexual surgery.

If it is lung adenocarcinoma, it may have metastasized to distant organs, organs, or distant lymph nodes through the blood system or lymphatic system when it is discovered, and it is difficult to achieve the goal of ** and ** through surgery.

For this type of disease, there are many ways, including the detection of gene mutations and driver genes. If the corresponding driver gene is found to be positive, appropriate targeting** can be used to prolong the survival of patients with advanced disease by 3-5 years, or the survival of some patients can be extended by 8-9 years, or even longer, to achieve the management of chronic diseases. In patients with negative driver genes, combination chemotherapy or single-agent immunization** generally yields good results.

Therefore, lung adenocarcinoma is not the most difficult malignant tumor.

If it is in the early stage, it should not be difficult, hold on and don't give up, there is hope!

Adenocarcinoma of the lungs is non-small cell lung cancer, and if it is a female patient, a positive gene targeting test indicates that the patient may have a gene targeted drug**. At this time, the recovery is better, and the survival period is 1 year, 2 years, or even longer. If lung adenocarcinoma metastasizes, surgical resection** cannot be performed, and chemotherapy can only be given.

In particular, for patients with negative gene targeted testing, it takes 4-6 times to determine the effect of chemotherapy. If the adenocarcinoma mass has significantly shrunk, dynamic observation and traditional Chinese medicine and immunization** are required. In short, whether lung adenocarcinoma is good or not is mainly closely related to gene targeted detection.

If the gene-targeted test is positive, the prognosis of the patient is better and the patient can survive for a longer time. If the gene targeting test is negative, the targeted drug cannot be given**, and surgical resection ** cannot be performed, only chemical ** can be given, and the survival time is about 1 year, and the prognosis is poor.

Lung adenocarcinoma, that is, lung adenocarcinoma, accounts for a relatively high proportion of all lung cancers, and whether it is serious depends not only on the pathological type, but also on the stage of the tumor, such as the size of the primary lesion, whether there is peripheral lymph node metastasis and distant metastasis, etc. Compared with the early stage of lung adenocarcinoma, the effect is relatively better, because surgery can be used, and if the tumor has invasive manifestations after surgery, chemotherapy is required. If there are a large number of surrounding lymph node metastases, radiotherapy can also be used.

In addition, if lung adenocarcinoma still has a glimmer of life in the advanced stage, targeted drugs can be considered**. If the targeted ** effect is effective, it can also prolong survival, but it is generally a malignant tumor, which must be more serious. There are still many targeted drugs that can be selected for lung adenocarcinoma, but genetic testing is generally done first.

If there is a gene mutation, it is better to use it, such as the commonly used Iressa, Trogkai, etc., which can be used for the targeting of lung adenocarcinoma**.

It is not a difficult disease to treat, it should be cooperated with immediately, and some drugs should be assisted, and it should also be paid attention to the conservative way to choose surgery at the right time.

The pre-adenocarcinoma of the right lung is not difficult**, and it can be solved only by **sexual surgery, but if it is detected late and the cancer cells have metastasized, then sorry, it is very difficult**.

Yes, all kinds of cancers are relatively difficult to treat. You should immediately go to the hospital for an examination, find out**, and make a **plan according to the doctor's advice.

If you are struggling with all kinds of cancer, you should immediately check for the cause of the cancer and make a medical plan according to the doctor's advice.

Some lung adenocarcinoma can be ** and some can't **, and the common ones are as follows:

1. Stage 1 and stage lung adenocarcinoma can be operated on**, and the 5-year survival rate can reach 70%, and this part of the patient can**. After neoadjuvant chemotherapy, surgery, and radiotherapy, 45% of patients with stage A lung adenocarcinoma can also have a survival rate of more than 5 years, and this part of patients can also **;

2. For stage C and stage lung adenocarcinoma, it cannot be completely **, but now there are targeted precision**, chemotherapy, radiotherapy, anti-angiogenic and immuno** methods, and the effect is also relatively good. The 3-year survival rate of patients with advanced lung adenocarcinoma can be 30%-40% after comprehensive**, and about 30% of patients with advanced lung adenocarcinoma can survive for a long time, but the 5-year survival rate is relatively poor.

In addition, it should be noted that an important way to increase the rate of lung adenocarcinoma** when detected early is the need for regular medical checkups. People over the age of 40 should have a non-contrast chest CT scan every 1 year, and those before the age of 40 should have a chest CT scan every 2 years.

Lung adenocarcinoma is a relatively common pathological type of lung cancer, which is generally possible, of course, it also depends on the size and stage of lung adenocarcinoma, which is a very important influencing factor in determining prognosis. For example, in the early stage of lung adenocarcinoma, lobectomy can be achieved through surgery, and some can achieve the best effect, and some do not need adjuvant chemotherapy after surgery. If there are local invasive manifestations, or the postoperative pathological stage indicates that it is not very early, it belongs to the middle or middle and late stages, in this case, adjuvant chemotherapy needs to be combined with postoperative chemotherapy, and the general first-line chemotherapy is pemetrexed and platinum-based regimen, and it can be combined with radiotherapy and other comprehensive ** at the same time as chemotherapy.

There are some targeted drugs to choose from for lung adenocarcinoma, you can do genetic testing first, if there are EGFR and other gene mutations, there are still more ways to choose, so it is possible, don't give up.

The best way to treat adenocarcinoma of the right lung depends on the stage of adenocarcinoma of the lung. If it is an early-stage lung adenocarcinoma, that is, the tumor is less than 3cm, there is no hilar lymph node metastasis, no mediastinal lymph node metastasis, and no supraclavicular lymph nodes or distant metastases, such as bone metastases, brain metastases, etc., surgery** is selected. After surgical resection, the need for postoperative assistance is determined based on postoperative pathology**.

The preoperative evaluation can be performed for **sexual surgical resection, and the postoperative pathology is diagnosed as early, and postoperative adjuvant radiotherapy, chemotherapy or targeting can be dispensed with.

If it is locally advanced lung adenocarcinoma or advanced lung adenocarcinoma, that is, the tumor is relatively large, and it is combined with mediastinal lymph node metastasis or supraclavicular lymph node metastasis, as well as brain metastases, liver metastases, etc., then it is necessary to see whether there is a gene mutation in lung adenocarcinoma. Targeted drugs can be used if there is a genetic mutation, and if there is no genetic mutation, immune checkpoint inhibitors or a combination of chemotherapy can be used**. In short, the best method for adenocarcinoma of the right lung is mainly to combine pathological staging and gene mutation to implement comprehensively.